Heart failure (HF) is when the heart doesn't pump blood well enough. This study tests if a drug called maridebart cafraglutide helps people with HF and obesity. It aims to see if it lowers hospital visits, heart-related deaths, and improves symptoms. The study is in two parts and will end part one after 850 heart-related events occur. People must be 18+, have a high BMI (over 30), and have a type of HF with a left ventricular ejection fraction (LVEF) over 40%. This means their heart's ability to pump blood is somewhat preserved. Exclusion criteria include recent major heart events, certain heart types, severe diabetes, or specific medical conditions.
- The study will have a double-blind period, meaning neither the participants nor researchers know who gets the actual drug or a placebo.
- Part 1 will conclude when about 850 heart-related events happen, which means it may take a while.
- Participants need to be committed, as it requires following specific health guidelines and possibly managing existing health issues.
How understandable was the trial content above?
Hard to understand
Easy to understand